Loading
TCF19 (Transcription factor 19) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
Potential transcription factor that may play a role in the regulation of genes involved in cell cycle G1/S transition. May bind to regulatory elements of genes, including the promoter of the transcription factor FOXO1.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Mirdametinib and Birabresib.
In plain words · TCF19 (Transcription factor 19) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
TCF19 (Transcription factor 19) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
Potential transcription factor that may play a role in the regulation of genes involved in cell cycle G1/S transition. May bind to regulatory elements of genes, including the promoter of the transcription factor FOXO1.
No product in this corpus aims at TCF19 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA TCF19: RNA low tissue specificity; no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas TCF19 tissue; Open Targets ENSG00000137310 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Ku D.H. et al, Cell Growth Differ, 1991, "A new growth-regulated complementary DNA with the sequence of a putative trans-activating factor". Source.
Sources: HGNC HGNC:11629 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9Y242 (protein name, function text, keywords and locations (REST API)); CIViC gene TCF19 (1 evidence items, 0 assertions, 1 variants; diseases: Melanoma (GraphQL API, CC0))
Potential transcription factor that may play a role in the regulation of genes involved in cell cycle G1/S transition. May bind to regulatory elements of genes, including the promoter of the transcription factor FOXO1. Location: Nucleus (UniProt). Locus 6p21.33 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"TCF19" OR ABSTRACT:"TCF19" OR TITLE:"transcription factor 19" OR ABSTRACT:"transcription factor 19" OR TITLE:"Transcription factor 19" OR ABSTRACT:"Transcription factor 19" OR TITLE:"SC1" OR ABSTRACT:"SC1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TCF19, not a curated reading list.